We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+29.89%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
+$361M
Cap. Flow
+$95.2M
Cap. Flow %
6.35%
Top 10 Hldgs %
63.32%
Holding
74
New
17
Increased
21
Reduced
30
Closed
4
Avg Time Held Equity + Options
1.4 years
Top 10 Avg Time Held Equity + Options
1.2 years
Top 20 Avg Time Held Equity + Options
1 year
Avg Time Held Equity only
1.5 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$33M
2
RVTY icon
Revvity
RVTY
+$31.9M
3
PFE icon
Pfizer
PFE
+$30.6M
4
VTRS icon
Viatris
VTRS
+$15.9M
5
INSP icon
Inspire Medical Systems
INSP
+$13.6M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$35.6M
2
IMGN icon
Immunogen Inc
IMGN
+$22.2M
3
ARGX icon
argenx
ARGX
+$12.1M
4
ILMN icon
Illumina
ILMN
+$12.1M
5
KRYS icon
Krystal Biotech
KRYS
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 89.26%
2 Miscellaneous 10.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MNKD icon
26
MannKind Corp
MNKD
$977M
$10.8M 0.72%
+2,391,128
New +$9.39M
2024 Q1
0 quarters
DHR icon
27
Danaher
DHR
$161B
$10.2M 0.68%
40,855
-186
-0.5% -$45.4K
2018 Q3
22 quarters
LLY icon
28
Eli Lilly
LLY
$1.12T
$10M 0.67%
+12,877
New +$9.16M
2024 Q1
0 quarters
ZIMV icon
29
DELISTED
ZimVie
ZIMV
$9.31M 0.62%
564,498
+18,054
+3% +$322K
2023 Q4
1 quarter
GH icon
30
Guardant Health
GH
$21.3B
$9.27M 0.62%
+449,586
New +$9.64M
2024 Q1
0 quarters
BKD icon
31
Brookdale Senior Living
BKD
$2.41B
$8.72M 0.58%
+1,318,765
New +$7.69M
2024 Q1
0 quarters
NAMS icon
32
NewAmsterdam Pharma
NAMS
$2.37B
$8.37M 0.56%
353,965
-20,439
-5% -$415K
2023 Q1
4 quarters
IMVT icon
33
Immunovant
IMVT
$5.52B
$8.26M 0.55%
255,526
+141,733
+125% +$5.17M
2023 Q4
1 quarter
NVO icon
34
Novo Nordisk
NVO
$171B
$8M 0.53%
+62,344
New +$7.42M
2024 Q1
0 quarters
KPTI icon
35
Karyopharm Therapeutics
KPTI
$8.85M
$7.57M 0.51%
+334,421
New +$5.86M
2024 Q1
0 quarters
PBYI icon
36
Puma Biotechnology
PBYI
$507M
$7.56M 0.5%
1,426,497
-268,524
-16% -$1.45M
2021 Q3
10 quarters
ELV icon
37
Elevance Health
ELV
$92.9B
$7.46M 0.5%
14,393
-701
-5% -$349K
2020 Q4
13 quarters
TVTX icon
38
Travere Therapeutics
TVTX
$4.68B
$7.37M 0.49%
+955,618
New +$8.06M
2024 Q1
0 quarters
CNC icon
39
Centene
CNC
$34.2B
$7.28M 0.49%
92,786
-4,412
-5% -$341K
2021 Q1
12 quarters
BCRX icon
40
BioCryst Pharmaceuticals
BCRX
$1.99B
$7.28M 0.49%
1,432,427
-96,620
-6% -$543K
2022 Q4
5 quarters
GOSS icon
41
Gossamer Bio
GOSS
$53.6M
$7.07M 0.47%
74,931
-5,478
-7% -$482K
2021 Q3
10 quarters
TSHA icon
42
Taysha Gene Therapies
TSHA
$1.18B
$6.67M 0.45%
2,325,591
-1,455,123
-38% -$3.03M
2023 Q3
2 quarters
TSVT icon
43
DELISTED
2seventy bio
TSVT
$6.3M 0.42%
1,177,678
+38,567
+3% +$181K
2023 Q3
2 quarters
STRO icon
44
Sutro Biopharma
STRO
$181M
$6.17M 0.41%
109,142
+3,496
+3% +$154K
2023 Q2
3 quarters
LQDA icon
45
Liquidia Corp
LQDA
$3.07B
$5.84M 0.39%
396,187
-292,739
-42% -$4.07M
2021 Q1
12 quarters
NVRO icon
46
DELISTED
NEVRO CORP.
NVRO
$5.63M 0.38%
+389,663
New +$6.44M
2024 Q1
0 quarters
AMRN icon
47
Amarin Corp
AMRN
$239M
$5.53M 0.37%
310,637
+5,862
+2% +$125K
2018 Q1
24 quarters
MRUS icon
48
DELISTED
Merus
MRUS
$5.38M 0.36%
119,482
+3,756
+3% +$152K
2021 Q4
9 quarters
ICLR icon
49
Icon
ICLR
$13.1B
$5.16M 0.34%
15,347
-70
-0.5% -$20.6K
2021 Q3
10 quarters
WAT icon
50
Waters Corp
WAT
$42.9B
$4.69M 0.31%
13,628
-14,091
-51% -$4.63M
2023 Q2
3 quarters
1
2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Eversept Partners held 74 positions worth $1.5B, up 32% from $1.14B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners deployed $95.2M of net new capital in Q1 2024, opening 17 new positions and adding to 21 existing holdings. Its largest new stake was Pfizer: 1,102,042 shares worth $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Natera, an estimated $35.6M trimmed.

  • Eversept Partners's largest Q1 2024 buy was Pfizer: 1,102,042 shares worth $30.6M.
  • Eversept Partners added most to GSK in Q1 2024, an estimated $33M increase.
  • Eversept Partners's biggest Q1 2024 reduction was Natera, cutting an estimated $35.6M.
  • Eversept Partners fully exited Immunogen Inc in Q1 2024, selling an estimated $22.2M.
  • Eversept Partners's ten largest holdings make up 63% of its $1.5B portfolio in Q1 2024.
  • Eversept Partners opened 17 new positions and closed 4 in Q1 2024.
  • Eversept Partners's portfolio value rose 32% quarter-over-quarter to $1.5B.

Based on Eversept Partners's 13F filing for Q1 2024, filed 15 May 2024.